Supported by data in patients with new-onset and relapsing giant cell arteritis (GCA), the FDA approved upadacitinib for the treatment of adults with GCA.
New Analysis Reveals More Potential Contributors to Takayasu Arteritis
Recent research led to development of a cumulative genetic risk score for Takayasu arteritis, identifying differing susceptibility between groups with different genetic ancestries.
Reactive Arthritis: Chronic or Self-Limiting?
Reactive arthritis has proved to be a diagnostic & therapeutic challenge due to its diverse presentations.
Psychosocial Factors & Pain in Hand Osteoarthritis
Attention to factors beyond the standard nociceptive model of painin patients with hand OA, including psychosocial considerations &other comorbidities, may impact a patient’s pain perception &pain course.
Rheuminations: Can We Now Control the Wolf?
Lupus has always had a reputation for being a wild, unrestrained and enigmatic entity. In fact, the very name lupus comes from the Latin word for wolf, a gift from our Roman predecessors who saw a resemblance between lupus rashes and a wolf’s bite. Given the limitations of immunology back then, it is an incredibly…
New Discoveries in Sjögren’s Disease
Although dryness and other symptoms of Sjögren’s disease continue to vex patients, the prospect of new treatments and a recent name change demonstrate advances in patient care.
FDA Approvals: Lupus Nephritis
Lupus nephritis is one of the leading causes of mortality for patients with systemic lupus erythematosus (SLE), and patients with both SLE and end-stage renal disease have standardized mortality ratios more than 60 times that of patients with SLE with normal kidney function.1 The good news: Rheumatologists now have not one, but two approved options…
Trials Find Potential Treatments for SLE, Lupus Nephritis
In summer 2024, two phase 3 studies were released with promising findings for the treatment of patients with systemic lupus erythematosus (SLE) and those with lupus nephritis. SLE Disease Activity Dapirolizumab pegol is a novel, investigational, Fc-free anti-CD40L agent for people living with moderate to severe SLE.1 The randomized, double-blind, parallel-group PHOENYCS GO trial (N=321)…
Belimumab Promising for Children with Lupus Nephritis
In late July 2022, the U.S. Food & Drug Administration (FDA) approved belimumab (Benlysta) for the treatment of children with active lupus nephritis aged 5 to 17 years old receiving standard therapy.1 Despite recent advances in treatment options for patients with systemic lupus erythematosus (SLE), those with kidney involvement may develop endstage renal disease and…
Kidney Biopsy in Lupus Nephritis
As part of a session on lupus nephritis at ACR Convergence 2023, Simone Appenzeller, MD, PhD, shared perspectives on the importance of biopsy to inform the diagnosis, prognosis and treatment of the condition, with an emphasis on childhood disease. Prompt diagnosis and treatment of lupus nephritis is perhaps even more important for children than for…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 344
- Next Page »